23:08 GMT [Dow Jones] CSL (CSL.AU), Australia's largest pharmaceuticals group, is nursing a cold from the flu-vaccines business it bought from Novartis in a deal that completed in August. CSL signaled a US$130 million underlying net loss on the business in FY16, contributing to Goldman Sachs lowering its FY16-FY18 EPS forecasts by 1%-6%. Still, the broker retains a buy call on the stock. "We believe investors will likely regards FY17 metrics as a better reflection of the company's underlying earnings (whereas FY16 incorporates flu losses ahead of the restructuring program)," analyst Ian Abbott says. CSL last traded at A$88.99. (david.winning@wsj.com; @dwinningWSJ)

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

October 15, 2015 19:22 ET (23:22 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.
Grafico Azioni CSL (ASX:CSL)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di CSL
Grafico Azioni CSL (ASX:CSL)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di CSL